Skip to main
NYXH

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah is a medical technology company with a promising outlook, as evidenced by its strong Q1 net-revenue of €6.4M and its increasing sales force, which is expected to continue growing. The company is on track to submit a PMA supplement for a complete concentric collapse indication in Q3 or early Q4, with U.S. label expansion expected by 2027. Despite a lower valuation multiple due to sector trends, Nyxoah's FY26 revenue guidance of €36-40M is above the Street's estimate and shows potential for the company to become a high-growth asset. Additional positive developments, such as the completion of the ACCCESS study in late June or early July 2026, could further boost investor confidence in the company's potential.

Bears say

Nyxoah is showing strong revenue growth and maintaining its guidance, however, its gross margin and operating expenses are not meeting expectations. Additionally, there may be confusion and risks regarding the adoption of its technology and potential for further funding needs. While the recent U.S. launch has been successful, potential bottlenecks in the reimbursement process and volatility in the market may impact the company's future performance.

Nyxoah SA (NYXH) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 3 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.